FDA accepts Karyopharm application for expanded Xpovio multiple myeloma use

The FDA has accepted for review Karyopharm Therapeutics’ (NASDAQ:KPTI) supplemental marketing application seeking approval to use Xpovio (selinexor) to treat multiple myeloma (MM) patients who have received at least one prior line of therapy. The agency’s action date will be in Q1 2021.

The FDA approved the nuclear export inhibitor a year ago for MM patients who have received at least four prior lines of treatment.

https://seekingalpha.com/news/3592516-fda-accepts-karyopharm-supplement-application-for-expanded-use-of-xpovio-in-multiple-myeloma